CytRx, a biopharmaceutical research and development company specializing in oncology, announced this month that its more potent version of the widely used chemotherapeutic agent doxorubicin, aldoxorubicin, demonstrated statistically significant efficacy (p<.0001) in the treatment of rapidly growing human brain (glioblastoma) cancer in the brains of animals. Favorable results from this confirmatory trial - conducted in collaboration with Louisiana State University (LSU) School of Medicine - are set to be presented next month in Amsterdam at the European Society for Medical Oncology.
“We are surprised and excited about the effectiveness demonstrated by aldoxorubicin in this particularly difficult-to-treat cancer,” commented Om Prakash, Ph.D., the study’s principal investigator and Research Professor of Medicine, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans. “It has been well documented that doxorubicin, although active against glioblastoma cancer cells in tissue culture, does not cross the blood-brain barrier, the body’s natural defense system protecting the brain, to effectively treat patients with brain tumors. In fact, in our study doxorubicin was no more effective than saline in suppressing glioblastoma tumor growth. We have shown that aldoxorubicin uptake is confined only to the tumor in the brain and does not enter normal brain tissue. Thus, we would expect toxicity in the central nervous system to be negligible. Our conclusion from this trial is that aldoxorubicin has the potential to safely shrink glioblastoma tumors which could dramatically prolong the average survival time in patients. We initially had observed a similar effect of aldoxorubicin on glioblastoma in a preliminary study, and are quite pleased to have confirmed the result in a larger, well-controlled study that included native doxorubicin.”
Shown to be superior to doxorubicin in seven different tumor types and animal models of cancer, including ovarian, lung, breast, and pancreatic cancer, as well as multiple myeloma, aldoxorubicin has also demonstrated activity in human trials for the treatment of soft tissue sarcomas and other cancers. CytRx has chosen aldoxorubicin as the first drug candidate the company is developing based on a novel linker technology that has proven ability to allow attachment of multiple chemotherapeutic agents and is designed to provide both greater anti-cancer activity and to mitigate the toxicity that limits these agents’ use.
CytRx is well known for its many clinical programs related to the treatment of tumors. The company actively promotes its findings by speaking at several gatherings within the healthcare field, such as the Annual ROTH conference; the Leerink Swann Global Healthcare conference; and the Biotech Showcase 2013 conference. Most recently, CytRx presented at the American Society of Clinical Oncology (ASCO) conference in Chicago, focusing on favorable findings from a Phase 1b clinical trial regarding the combination of aldoxorubicin and doxorubicin.
For more information on CytRx, please visit www.cytrx.com
CytRx Corp. (CYTR) to Present at the European Society for Medical Oncology Conference in Amsterdam
CytRx, a biopharmaceutical research and development company specializing in oncology, announced this month that its more potent version of the widely used chemotherapeutic agent doxorubicin, aldoxorubicin, demonstrated statistically significant efficacy (p<.0001) in the treatment of rapidly growing human brain (glioblastoma) cancer in the brains of animals. Favorable results from this confirmatory trial - conducted in collaboration with Louisiana State University (LSU) School of Medicine - are set to be presented next month in Amsterdam at the European Society for Medical Oncology.
“We are surprised and excited about the effectiveness demonstrated by aldoxorubicin in this particularly difficult-to-treat cancer,” commented Om Prakash, Ph.D., the study’s principal investigator and Research Professor of Medicine, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans. “It has been well documented that doxorubicin, although active against glioblastoma cancer cells in tissue culture, does not cross the blood-brain barrier, the body’s natural defense system protecting the brain, to effectively treat patients with brain tumors. In fact, in our study doxorubicin was no more effective than saline in suppressing glioblastoma tumor growth. We have shown that aldoxorubicin uptake is confined only to the tumor in the brain and does not enter normal brain tissue. Thus, we would expect toxicity in the central nervous system to be negligible. Our conclusion from this trial is that aldoxorubicin has the potential to safely shrink glioblastoma tumors which could dramatically prolong the average survival time in patients. We initially had observed a similar effect of aldoxorubicin on glioblastoma in a preliminary study, and are quite pleased to have confirmed the result in a larger, well-controlled study that included native doxorubicin.”
Shown to be superior to doxorubicin in seven different tumor types and animal models of cancer, including ovarian, lung, breast, and pancreatic cancer, as well as multiple myeloma, aldoxorubicin has also demonstrated activity in human trials for the treatment of soft tissue sarcomas and other cancers. CytRx has chosen aldoxorubicin as the first drug candidate the company is developing based on a novel linker technology that has proven ability to allow attachment of multiple chemotherapeutic agents and is designed to provide both greater anti-cancer activity and to mitigate the toxicity that limits these agents’ use.
CytRx is well known for its many clinical programs related to the treatment of tumors. The company actively promotes its findings by speaking at several gatherings within the healthcare field, such as the Annual ROTH conference; the Leerink Swann Global Healthcare conference; and the Biotech Showcase 2013 conference. Most recently, CytRx presented at the American Society of Clinical Oncology (ASCO) conference in Chicago, focusing on favorable findings from a Phase 1b clinical trial regarding the combination of aldoxorubicin and doxorubicin.
For more information on CytRx, please visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
